Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma

Research output: Contribution to journalArticle


  • AT Chan
  • SF Leung
  • RK Ngan
  • PM Teo
  • WH Law
  • WH Kwan
  • EP Hui
  • HY Yiu
  • W Yeo
  • FY Cheung
  • KH Yu
  • KW Chiu
  • DT Chan
  • TS Mok
  • S Yau
  • KT Yuen
  • FK Mo
  • MM Kai
  • BB Ma
  • MK Kam
  • TW Leung

Colleges, School and Institutes


This phase III randomized study compared concurrent cisplatin-radiotherapy (CRT) versus radiotherapy (RT) alone in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 350 patients were randomly assigned to receive external RT alone or concurrently with cisplatin at a dosage of 40 mg/m(2) weekly. The primary endpoint was overall survival, and the median follow-up was 5.5 years. The 5-year overall survival was 58.6% (95% confidence interval [CI] = 50.9% to 66.2%) for the RT arm and 70.3% (95% CI = 63.4% to 77.3%) for the CRT arm. In Cox regression analysis adjusted for T stage, age, and overall stage, the difference in overall survival was statistically significantly in favor of concurrent CRT (P = .049, hazard ratio [HR] = 0.71 [95% CI = 0.5 to 1.0]). Subgroup analysis demonstrated that there was no difference between overall survival in the arms for T1/T2 stage (P = .74, HR = 0.93 [95% CI = 0.59 to 1.4]), whereas there was a difference between the arms for T3/T4 stage (P = .013, HR = 0.51 [95% CI = 0.3 to 0.88]), favoring the CRT arm. The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients.


Original languageEnglish
Pages (from-to)536-539
Number of pages4
JournalJournal of the National Cancer Institute
Publication statusPublished - 6 Apr 2005